IL6 and nasopharyngeal carcinoma: Our findings here showed that recombinant adiponectin or specific adiponectin receptor agonist, AdipoRon, could block NF-κB and STAT3 activation signaling (including leptin-, IL-6- or TNF-α-induced activation of STAT3 and NF-κB) in NPC cells.